NexgenRx Inc.
NEGXF
$0.1964
$0.00492.56%
OTC PK
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 11.61M | 11.50M | 11.48M | 11.27M | 10.75M |
| Total Other Revenue | 563.80K | 459.70K | 421.20K | 447.60K | 450.50K |
| Total Revenue | 12.18M | 11.96M | 11.91M | 11.72M | 11.20M |
| Cost of Revenue | 2.35M | 2.38M | 2.33M | 2.53M | 2.35M |
| Gross Profit | 9.83M | 9.58M | 9.58M | 9.19M | 8.85M |
| SG&A Expenses | 7.84M | 7.77M | 7.78M | 7.90M | 7.75M |
| Depreciation & Amortization | 904.90K | 907.00K | 924.70K | 933.30K | 946.30K |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 11.09M | 11.05M | 11.03M | 11.36M | 11.05M |
| Operating Income | 1.08M | 900.40K | 873.00K | 355.20K | 148.00K |
| Income Before Tax | 1.01M | 774.40K | 747.90K | 208.40K | 2.30K |
| Income Tax Expenses | 294.20K | 294.00K | 292.90K | 18.60K | 19.50K |
| Earnings from Continuing Operations | 0.71 | 0.48 | 0.45 | 0.19 | -0.02 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 712.50K | 480.30K | 454.90K | 189.70K | -17.20K |
| EBIT | 1.08M | 900.40K | 873.00K | 355.20K | 148.00K |
| EBITDA | 1.78M | 1.60M | 1.61M | 1.28M | 1.08M |
| EPS Basic | 0.01 | 0.00 | 0.00 | 0.00 | 0.00 |
| Normalized Basic EPS | 0.01 | 0.01 | 0.01 | 0.00 | 0.00 |
| EPS Diluted | 0.01 | 0.00 | 0.00 | 0.00 | 0.00 |
| Normalized Diluted EPS | 0.01 | 0.01 | 0.01 | 0.00 | 0.00 |
| Average Basic Shares Outstanding | 283.78M | 283.59M | 283.39M | 283.46M | 282.91M |
| Average Diluted Shares Outstanding | 300.78M | 300.78M | 296.79M | 296.85M | 296.00M |
| Dividend Per Share | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 |
| Payout Ratio | 56.27% | 83.97% | 88.99% | 337.22% | -3,721.51% |